u/farid_molnar

phase 2 data only, and people quote it like it is a label

Disagree with this specific inference. A 48-week readout does not tell you the shape of the curve after it.

nothing here is available as a prescription product, so read every thread with that in mind

That is body weight change, not fat mass. The trials report the first and people quote it as the second.

phase 2 data only, and people quote it like it is a label

Same read. The energy-expenditure mechanism is the interesting bit and it is not established in humans at scale.

dose escalation in the trials was slow for a reason

Nothing containing this compound is approved anywhere. Research-use-only material is not approved for human use, and that is a statement of fact rather than a disclaimer.

The phase 2 readout ran to 48 weeks in a few hundred participants with a slow escalation. Both the size and the duration matter when people quote the headline number.

Agreed on the heart-rate reports. They are consistent enough across the threads to be worth noting, not enough to be a finding.

Glucagon receptor agonism is associated with increased energy expenditure and with hepatic effects. That is a mechanistic story with strong preclinical support and limited phase 2 human data.

Yes — the glucagon arm is what makes it a different proposition rather than a stronger version of the others.

Nothing containing this compound is approved anywhere. Research-use-only material is not approved for human use, and that is a statement of fact rather than a disclaimer.

Kept a log specifically because there is so little published. It is one person and it is not data.

Phase 2 estimates effect and finds a dose range. Phase 3 estimates it precisely in a bigger population and catches what phase 2 was too small to see. Treating them as the same tier of evidence is the recurring error here.

Not convinced. You are attributing a week of fatigue to the glucagon arm when the escalation rate alone would explain it.

triple agonist — GLP-1, GIP and glucagon, and the glucagon arm is the new part

ismael_eriksen is right about the escalation being the variable. It explains most of the difficult reports here.

It is a triple agonist at the GLP-1, GIP and glucagon receptors. The glucagon arm is the genuinely novel component and it is the one with the least human outcome data behind it.

the glucagon component is why the metabolic story reads differently

This is the sentence the rest of the board should read first. Phase 2 is not a label.

a lot of the confident posting here is extrapolation

How fast was the escalation? That is usually the variable that explains the reports.

the glucagon component is why the metabolic story reads differently

Watched heart rate on a wearable across twelve weeks because the threads said to.

This is the sentence the rest of the board should read first. Phase 2 is not a label.

Not convinced. You are attributing a week of fatigue to the glucagon arm when the escalation rate alone would explain it.

heart rate is the thing people report watching

triple agonist — GLP-1, GIP and glucagon, and the glucagon arm is the new part

The phase 2 readout ran to 48 weeks in a few hundred participants with a slow escalation. Both the size and the duration matter when people quote the headline number.

nothing here is available as a prescription product, so read every thread with that in mind

It is a triple agonist at the GLP-1, GIP and glucagon receptors. The glucagon arm is the genuinely novel component and it is the one with the least human outcome data behind it.

heart rate is the thing people report watching

Phase 2 estimates effect and finds a dose range. Phase 3 estimates it precisely in a bigger population and catches what phase 2 was too small to see. Treating them as the same tier of evidence is the recurring error here.

Yes — the glucagon arm is what makes it a different proposition rather than a stronger version of the others.